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ABSTRACT: The Bromo- and Extra-Terminal (BET) proteins
BRD2, BRD3, and BRD4 play important roles in transcriptional
regulation, epigenetics, and cancer and are the targets of pan-BET
selective bromodomain inhibitor JQ1. However, the lack of intra-
BET selectivity limits the scope of current inhibitors as probes for
target validation and could lead to unwanted side eﬀects or toxicity
in a therapeutic setting. We designed Proteolysis Targeted
Chimeras (PROTACs) that tether JQ1 to a ligand for the E3
ubiquitin ligase VHL, aimed at triggering the intracellular
destruction of BET proteins. Compound MZ1 potently and
rapidly induces reversible, long-lasting, and unexpectedly selective
removal of BRD4 over BRD2 and BRD3. The activity of MZ1 is dependent on binding to VHL but is achieved at a suﬃciently
low concentration not to induce stabilization of HIF-1α. Gene expression proﬁles of selected cancer-related genes responsive to
JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4.
Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with
selective targeting of BRD4.
The Bromo- and Extra-terminal (BET) family of proteins,including the ubiquitously expressed BRD2, BRD3, and
BRD4 and the testis-speciﬁc BRDT, recruit transcriptional
regulatory complexes to acetylated chromatin thereby control-
ling speciﬁc networks of genes involved in cellular proliferation
and cell cycle progression.1 Deregulation of BET protein
activity, in particular BRD4, has been strongly linked to cancer
and inﬂammatory diseases, making BET proteins attractive
drug targets.2 For example, RNAi screens have identiﬁed BRD4
as a therapeutic target in acute myeloid leukemia,3 ovarian
carcinoma,4 and siRNA knock down of BRD4, but not of BRD2
or BRD3, induced upregulation of apolipoprotein A1 (ApoA1),
which protects from atherosclerosis progression and other
inﬂammatory processes.5 The silencing of BRD4 furthermore
identiﬁed BRD4 as a target to treat chronic obstructive
pulmonary disease (COPD).6 These results underscore the
potential of targeting BRD4 as a therapeutic strategy and
motivate further research in validating BRD4 as a drug target.
Crucial to the function of BET proteins are two highly
homologous bromodomains that are present in their amino-
terminal regions and direct recruitment to nucleosomes by
binding to speciﬁc acetylated lysines (KAc) within histone tails.
7
Small molecule BET inhibitors, including the triazolodiazepine-
based JQ18 and I-BET7629 (Figure 1a) among others,10−13
bind to the KAc-binding pocket of the bromodomains and
disrupt interaction with histones, thereby displacing BET
proteins and their associated transcriptional regulatory
complexes from chromatin. BET inhibitors are highly potent
(Kd ∼100 nM), cell-penetrant, and active in vivo against a range
of solid, hematological, and other tumors, which has prompted
compounds entering phase I clinical trials for cancer.14−16
However, BET inhibitors show no selectivity for individual
BET family members, thereby limiting their scope as chemical
probes for validating the roles of individual BET targets in
physiology and disease. To this end, chemical genetic strategies
have been recently developed to engineer orthogonal selective
BET bromodomain-ligand pairs.17 While this approach has the
advantage of enabling disruption at will of a single or more
bromodomains, it requires a mutation to be introduced into the
target protein. Therapeutically, the eﬀects of BET inhibitors on
diﬀerent transcriptional pathways have raised concerns about
the safety and tolerability of BET inhibitors in humans.
Crucially, none of the inhibitors described to date is selective
for binding BRD4 bromodomains over those of its paralogs
BRD2 and BRD3.
Small molecule chemical probes or inhibitors acting at the
post-translational level hold several advantages for target
validation over genetic techniques such as dominant-negative
mutants or knockouts and RNAi knockdowns, including
aﬀording spatial and temporal control in a reversible fashion.
A general limitation associated with conventional occupancy-
driven target inhibition is that it often demands full target
engagement, requiring sustained high concentration of a potent
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small molecule inhibitor over a prolonged time. This in turn
enhances oﬀ-target eﬀects and can lead to unwanted side eﬀects
or toxicity in a therapeutic setting. To provide an alternative
small molecule approach that could address these issues, we
hypothesized that it would be possible to design a molecule that
can remove BET proteins entirely from the cell as opposed to
just inhibit them, yielding new tools for studying BET
bromodomain proteins and validating them as drug targets.
In order to achieve intracellular BET-protein degradation, we
applied a small molecule PROTAC (Proteolysis Targeting
Chimera) approach.18,19 A PROTAC is a heterobifunctional
compound that contains two ligands connected by a linker unit.
One ligand binds an E3 ubiquitin ligase protein, while the other
ligand binds to the target protein of interest, thereby bringing
the ligase and the target in close proximity. This in turn triggers
the polyubiquitination and subsequent proteasome-dependent
degradation of the target. Proof-of-concept examples have been
described where PROTACs were used to degrade the
estrogen20- and androgen-receptor,21 methionine aminopepti-
dase-2,22 as well as the aryl hydrocarbon receptor.23 However,
all ﬁrst-generation PROTACs included a peptidic moiety as the
E3 ligase ligand. For example, a hydroxyproline-containing
heptapeptide sequence ALA-Hyp-YIP from the transcription
factor Hypoxia-Inducible Factor 1 alpha subunit (HIF-1α) has
been widely used,24 as this represents the minimal epitope for
HIF-1α binding to the ubiquitously expressed E3 ligase von
Hippel-Lindau protein (VHL).25 The high peptidic nature of
the ﬁrst-generation PROTACs resulted in poor physicochem-
ical properties such as low intracellular stability and poor cell
permeability, which limited their applicability as chemical
probes and their potential therapeutic development. To
overcome these limitations here, we develop a nonpeptidic
PROTAC approach that exploits our recently discovered and
optimized drug-like VHL ligands26 and show that it can be
applied to target BET bromodomains and potently induce
eﬀective and selective degradation of BRD4.
We began by designing a series of PROTACs that would link
together speciﬁc VHL ligands and BET bromodomain ligands.
Recent work has established compounds VHL-1 and VHL-2 as
strong binders with Kd values below 300 nM to VHL (Figure
1a).26 Inspection of the protein−ligand crystal structures show
that the methyl group of the terminal acetyl groups in
compounds VHL-1 and VHL-2 is solvent exposed, and we
therefore reasoned that it could provide a suitable connecting
point for a linker (Figure S1). The BET inhibitor JQ18 was
chosen as the bromodomains-recruiting scaﬀold, and its t-butyl
ester group was selected as a connecting point for a linker
because it is solvent-exposed and not involved in key
Figure 1. Design, synthesis, and biophysical and biological evaluation of BET bromodomain PROTACs. (a) Chemical structures of BET-
bromodomain inhibitors JQ1 and I-BET762 and binders of von Hippel-Lindau protein VHL-1 and VHL-2. (b) Scheme of the synthesis of PROTAC
compounds MZ1−3 and cisMZ1; for detailed synthetic procedures see the Supporting Information. (c) Isothermal titration calorimetry data for
titration of MZ1 into the individual members of the BET-bromodomain subfamily. Titrations were performed at 30 °C with a protein concentration
of 15 μM and ligand concentration of 150 μM (entry 1−6). Titration of MZ1 and cisMZ1 into VBC at 25 °C with identical concentrations (entry 9,
12) and reverse titration of VBC protein (150 μM) into MZ3 (15 μM) at 25 °C (entry 10) were conducted. For ΔS and ΔG values, see the
Supporting Information. (d) HeLa cells were treated with either siRNA targeting individual BET proteins or negative control siRNA 24 h prior to
treatment with the compounds MZ1−3, cisMZ1, and JQ1 or vehicle control (0.01% DMSO) for an additional 24 h. Abundance of individual BET
protein was analyzed by Western blotting using corresponding speciﬁc antibodies accordingly after SDS-PAGE. i, data from ref 8; ii, data from ref 26.
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interaction with the BET bromodomains as revealed by
cocrystal structures (Figure S1). Linkers with diﬀerent lengths
comprised of polyethylene glycol chains with either three or
four ethylene glycol units were chosen to connect JQ1 with the
VHL ligand. To achieve the desired ligands, a generally
applicable two-step synthetic strategy was devised. First, the
linker bearing a carboxylic acid at one end and an azide group at
the other end was connected with the terminal free amine of
the VHL ligand by a HATU-mediated amide bond formation.
In the second step, reduction of the azide group to an amine
and subsequent amide bond formation with the carboxylic acid
of the ester-hydrolyzed JQ1 analogue aﬀorded the desired
PROTAC compounds MZ1, MZ2, MZ3, and cisMZ1 (Figure
1b).
To assess whether PROTAC molecules retained their
binding to the target proteins VHL and BET bromodomains
in a similar fashion as the parental ligands, isothermal titration
calorimetry (ITC) experiments were performed (Figure 1; all
ITC titrations are shown in the Supporting Information). MZ1,
as a representative of all PROTAC molecules that share the
same JQ1 moiety for binding bromodomains, was titrated into
individual ﬁrst and second bromodomains of BRD2, BRD3, and
BRD4 (Figure 1c, entries 1−6). The measured binding aﬃnities
(Kd of 115−382 nM) and ΔH (−6.1 to −10.0 kcal/mol)
compared well with those reported for unmodiﬁed JQ18
(literature values for BRD4 bromodomains shown in Figure 1c,
entries 7, 8), suggesting that JQ1 binding mode is conserved
within the context of our PROTACs. Similarly, as binding to
Figure 2. PROTACs induce concentration- and time-dependent selective degradation of BRD4. (a) HeLa cells treated for 24 h with diﬀerent
concentrations of MZ1 (panel I), MZ2 (panel II), and MZ3 (panel III). The bands observed in the BRD4 short isoform lane at a high concentration
of each compound are correlated to nonspeciﬁc binding. (b) Time dependent treatment over 36 h of HeLa cells with 1 μM (panel I) and 100 nM
(panel II) of MZ1. (c) U2OS cells transfected with GFP-BRD4 were treated with either 5 μM of MZ1 or cisMZ1 over a time course of 4 h. BRD4
degradation over time was followed by live ﬂuorescence imaging.
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the VHL protein is crucial for the recruitment of target proteins
to the E3 ligase, the binding of MZ1 and MZ3 to the VHL-
ElonginB-ElonginC complex (VBC) was also quantiﬁed using
ITC (Figure 1c, entries 9, 10). The measured aﬃnities (Kd of
150 and 310 nM for MZ1 and MZ3, respectively) and ΔH
(−6.9 and −4.9 kcal/mol, respectively) compared very closely
to those of the parental unmodiﬁed ligands VHL-1 (Kd = 185
nM, ΔH = −5.5 kcal/mol, entry 11) and VHL-2 (Kd = 290 nM,
ΔH = −5.3 kcal/mol).26 As the stereochemistry of the hydroxyl
group of the central hydroxyproline moiety is crucial for ligand
binding to VHL, compound cisMZ1 was synthesized that is
structurally identical to MZ1 except for a reversed stereocenter
at the C-4 position bearing the hydroxyl group. As expected,
cisMZ1 did not exhibit any measurable binding aﬃnity for VHL
in the ITC experiment (Figure 1c, entry 12) and thus was
elected as a negative control compound in cellular assays.
To demonstrate that PROTACs are able to induce
degradation of BET proteins, HeLa cells transfected with
control siRNA were treated with 1 μM of compounds MZ1−3
alongside negative controls JQ1 and cisMZ1 for 24 h (Figure
1d). In parallel, HeLa cells with BRD2, BRD3, and BRD4
individually and separately silenced by transfection with the
respective siRNA were treated with vehicle DMSO to compare
the protein depletion eﬀect of RNAi knockdown and
PROTACs. BET protein abundance was evaluated by SDS-
PAGE followed by Western blot using corresponding speciﬁc
antibodies to probe for BRD2, BRD3 or BRD4, respectively. All
three PROTAC compounds demonstrated complete removal
of BRD4 with no detectable protein observed after 24 h of
treatment. In contrast, removal of BRD2 and BRD3 was not
complete after 24 h. MZ1 exhibited the highest eﬃcacy among
the three compounds. MZ2, which is structurally analogous to
MZ1 except for a longer linker containing four PEG units,
showed a weaker removal eﬀect compared to MZ1. MZ3,
containing an additional phenylalanine moiety between the
linker and the VHL ligand, showed to be the least eﬀective at
removing BRD2 and BRD3. Together, the data demonstrate
potent and eﬀective degradation of BET proteins and suggested
a preferential degradation eﬀect on BRD4 over BRD2 and
BRD3. The latter observation was unexpected given the
parental compound JQ1 is a pan-BET inhibitor and our
PROTACs bind with similar aﬃnities to BET bromodomains.
Nevertheless, the attractive opportunity to achieve single target
selectivity prompted us to conduct further characterization.
To assess the compound dose- and time-dependent
intracellular activities, HeLa cells were ﬁrst treated with various
concentrations of MZ1, MZ2, and MZ3 (Figure 2a). All three
compounds showed concentration dependent BET removal
activity with higher activity at higher concentrations. As in the
initial experiment, MZ1 proved the most active compound,
with more than 90% of all BET proteins being removed at
compound concentration down to 1 μM. Remarkably,
preferential removal of BRD4 over BRD2 and BRD3 was
conﬁrmed with all three compounds. Such preference is more
prominent with treatment at lower concentrations, e.g., 0.1−0.5
μM. To study the activities of our PROTACs over time, HeLa
cells were treated with 1 μM or 0.1 μM MZ1, and cellular BET
protein levels were monitored in a time course experiment
(Figure 2b for representative data with MZ1, see Figure S2 for
additional data with other compounds and concentrations).
Progressive removal of BET proteins over time was observed in
all experimental setups, and BRD4 consistently exhibited the
strongest and fastest reduction in protein level. Reassuringly, no
BET protein degradation was observed in the presence of either
DMSO or JQ1 (Figure S3) or cisMZ1 (Figure 3a). To verify
whether the observation of preferential removal for BRD4 by
Figure 3. Mechanistic studies on PROTAC biological activity. (a) Time dependent treatment over 36 h of HeLa cells with 1 μM inactive compound
cisMZ1. (b) HeLa cells treated with JQ1 or MZ1 at 1 μM in the absence or presence of the proteasome inhibitor MG132. (c) Time dependent
treatment over 36 h of HeLa cells with 1 μM MZ1 observing the levels of the von Hippel-Lindau (VHL) protein. (d) HeLa cells treated with 100
μM CoCl2 as a hypoxia control or 0.1, 1, and 10 μMMZ1. (e) BRD4 protein levels were observed (panel I) with single treatment of MZ1 at t = 0 for
4 h and then exchange of media, (panel II) single treatment with MZ1 at t = 0 but no exchange of media, and (panel III) single treatment with 0.01%
DMSO for 4 h and then exchange of media.
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our PROTACs can be observed in another cell line, the same
study was carried out in U2OS osteosarcoma cells, and the
same activity proﬁle was observed (Figure S4). To visualize the
BET protein degradation process, U2OS cells were transfected
with a plasmid coding for a green ﬂuorescent protein (GFP)
tagged BRD4 protein, allowing ﬂuorescence readout of BRD4
within the cell nuclei. Cells were induced to express GFP-BRD4
for 24 h and then were treated with either 5 μM MZ1 or 5 μM
cisMZ1, and the ﬂuorescence was observed over time. In the
presence of the active compound MZ1, a complete depletion of
the ﬂuorescence signal was observed after just 3 h, whereas
cisMZ1 caused no change in the ﬂuorescence signal over the
course of the experiment (Figure 2c, Figure S5 and Supporting
Information videos a and b). These data conﬁrmed that BRD4
is removed from the cell nuclei in a time dependent manner
due to the presence of MZ1. Taken together, time and dose−
response activity proﬁles revealed rapid and eﬀective PROTAC-
induced preferential degradation of BRD4 over BRD2 and
BRD3.
To gain mechanistic insights, the VHL and proteasome
dependency of PROTAC-mediated protein degradation was
ﬁrst examined. cisMZ1 was unable to induce degradation of any
of the BET proteins over time (Figure 3a), demonstrating that
PROTAC eﬃcacy is dependent on productive recruitment of
VHL. Next, the reliance of the PROTAC-induced protein
degradation on proteasome activity was assessed using
proteasome inhibitor MG132. Treatment with MG132
completely abrogated MZ1-induced degradation of all BET
proteins (compare lanes 3 and 6 in Figure 3b), establishing the
expected proteasome-dependence of the approach. Interest-
ingly, MG132 treatment in the absence of PROTAC showed
no signiﬁcant accumulation in BET protein levels, either alone
or in combination with JQ1 (compare lanes 1 and 2 with 4 and
5 in Figure 3b, respectively), suggesting that basal proteasome
activity level against BET proteins is negligible under those
conditions and only becomes signiﬁcant as a result of PROTAC
treatment.
To further evaluate the biological activity of our compounds,
we asked whether PROTAC treatment had any eﬀect on the
levels of its target E3 ligase (VHL) and on the level of HIF-1α,
the natural substrate of VHL. VHL levels in the presence of
MZ1 (1 μM) remained unaﬀected over the course of up to 36
h, thus indicating that the amount of E3 ligase is not inﬂuenced
by MZ1 binding (Figure 3c). On the other hand, as the VHL
ligand portions of our PROTACs occupy the same binding site
on VHL that is used to recruit HIF-1α, PROTACs could block
HIF-1α binding to VHL to an extent that it may lead to
potential stabilization of HIF-1α within cells. For the approach
herein described, this eﬀect would not be desirable as up-
regulation of HIF-1α transcriptional activity would confound
the eﬀects resulting from degradation of BET proteins and
would be expected to result in induction of the hypoxic
response, potentially giving rise to unwanted side eﬀects. To
assess whether any HIF-1α stabilization could be observed,
HeLa cells were treated with MZ1 and with cobalt(II) chloride
as a hypoxia mimicking positive control. Reassuringly, we could
not observe any evidence of HIF-1α stabilization even at
concentrations of MZ1 up to 10 μM, while clear HIF-1α
stabilization is observed in the presence of CoCl2 (Figure 3d).
A number of non-BET potential oﬀ-targets of JQ1 have been
recently reported, among which proteins DDB1 and RAD23B
(hHR23b) were validated by proteome labeling and Western
blotting.27 To assess whether MZ1 causes degradation of these
oﬀ-targets, protein levels were examined in HeLa cells treated
with MZ1 at 1 μM and 100 nM over a time course of 36 h, and
no degradation was observed (Figure S6). Next, to determine
whether the removal of BET proteins by PROTAC treatment is
reversible, and to establish how long it would take for cells to
reverse the eﬀect, we treated HeLa cells for 4 h with 1 μM of
MZ1, removed the compound from the media, and then
monitored protein levels over a period of 48 h. The washed
cells showed detectable recovery of intracellular BRD4 only by
20 h after washout, while in the absence of the wash step, no
protein could be detected even after 48 h (Figure 3e, see Figure
S7 for the same experiment monitoring time-dependent levels
of BRD2 and BRD3). Taken together, these results
demonstrate that PROTAC-induced protein degradation is
strictly dependent on binding to VHL, on proteasome activity,
and does not interfere with the normal endogenous levels of
both VHL and HIF-1α. Furthermore, the degradation eﬀect is
not only rapid but also sustained and long lasting even upon
removal of the compound.
BET inhibitors such as JQ1 inﬂuence the expression of an
assortment of genes.28 Selective targeting of individual BET
family members would be predicted to elicit distinct and more
limited transcriptional responses, because the genome
occupancy patterns of BET proteins are not identical.29 To
evaluate the functional consequences of removing BET proteins
using PROTACs, and in particular of inducing selective
degradation of BRD4 over BRD2 and BRD3, we next
monitored the mRNA expression proﬁles of a selection of
cancer-related genes which respond to JQ1 treatment and BET
protein inhibition: MYC, P21, AREG, FAS, TYRO3, and
FGFR1. The dependence of MYC and P21 expression on
BRD4 activity is well characterized. MYC stimulates cell cycle
progression and is constantly expressed upon misregulation in
cancer, thus leading to continuous overexpression of down-
stream MYC-dependent genes.30 In bone associated tumors31
as well as leukemia and lymphoma cell lines,32 JQ1 treatment or
silencing of BRD4 resulted in downregulation of MYC. MYC
represses transcription of the cell cycle CDK inhibitor P21, a
tumor suppressor.33 Downregulation of MYC and consequent
derepression of P21 promotes cell cycle arrest. In contrast to
the well characterized BRD4 dependency of MYC and P21,
FAS, which encodes a proapoptotic protein belonging to the
tumor necrosis factor receptor family,34 is downregulated by
depletion of BRD2,35 while for the growth factors AREG and
FGFR1 as well as the protein tyrosine kinase TYRO3 little is
known about any BET protein speciﬁc regulation. However,
these four genes are known to strongly respond to treatment
with JQ136 and therefore were included as a representative set
of genes to compare between the pan-BET inhibitory eﬀect
caused by JQ1 and a selective BRD4 degradation caused by
MZ1. Treatment with MZ1 at 100 nM for 24 h was chosen as
this provided an optimal condition and the lowest eﬀective
concentration for achieving selective degradation of BRD4 over
BRD2 and BRD3 and at the same time minimizing potential
interference due to BET bromodomain inhibition (Figure 2a
panel I and Figure 2b panel II). In addition, treatments with
negative control compound VHL-1′ (Figure S8) lacking the
JQ1 moiety, as well as with JQ1 itself, were also conducted to
provide comparisons. Treatment of MZ1 resulted in down
regulation of MYC, similar to JQ1, after 12 h (Figure S9),
although MYC levels recovered after 24 h. Treatment with MZ1
and JQ1 resulted in similar upregulation of P21 and AREG both
after 12 h (Figure S9) and 24 h (Figure 4a). Interestingly, in
ACS Chemical Biology Letters
DOI: 10.1021/acschembio.5b00216
ACS Chem. Biol. 2015, 10, 1770−1777
1774
contrast to JQ1, which resulted in signiﬁcant changes on FAS,
TYRO3, and FGFR1, MZ1 showed more subtle and less
signiﬁcant eﬀects on these genes relative to VHL-1′ (Figure 4a
and Figure S9). We hypothesize that such diﬀerences observed
in gene modulation may be the result of preferential
degradation of BRD4 over the other two BET proteins caused
by MZ1. To test this hypothesis, we suppressed individual
BRD2, BRD3, or BRD4 genes using siRNA to mimic the
protein removal eﬀect (Figure S10) and analyzed the gene
expression level of the target genes of interest (Figure 4b).
While MYC, P21, and AREG levels were conﬁrmed to be
aﬀected by suppression of BRD4, we found that FAS was
downregulated upon suppression of BRD2 only but not BRD4
(Figure 4b), while FGFR1 is upregulated upon suppression of
either BRD3 or BRD4. These results are consistent with
preferential degradation of BRD4 over BRD2 and BRD3 by
MZ1 and point to a more BRD4-selective pharmacological
proﬁle of MZ1 compared with pan-selective inhibitor JQ1.
In summary, we report a small molecule PROTAC approach
achieving rapid, eﬀective, and prolonged intracellular degrada-
tion of BET bromodomain proteins. The PROTAC-induced
protein degradation is dependent on binding to VHL, is
reversed upon blocking proteasome activity, and does not
interfere with the endogenous, physiological levels of VHL and
of its natural substrate HIF-1α. All investigated compounds
showed preferential degradation of BRD4 over BRD2 and
BRD3 at low concentrations. The downstream gene expression
pattern resulting from treatment with our potent and selective
PROTAC MZ1 is similar to JQ1 inhibition for BRD4-
dependent genes MYC, P21, and AREG but not for FAS,
FGFR1, and TYRO3. Our results suggest a diﬀerent
pharmacological response resulting from selectively depleting
BRD4 with MZ1 compared to inhibiting the whole BET
protein subfamily with JQ1. Given that no preference for
binding the bromodomains of BRD4 over the highly
homologous bromodomains of BRD2 and BRD3 was observed
by ITC within the context of the puriﬁed proteins, we speculate
that the observed selectivity could arise from preferential and
more eﬃcient polyubiquitination of lysine residues on the
surface of BRD4 compared to those of BRD2 and BRD3.
Alternatively or in addition, preferential direct interaction or
reduced steric constraints between VHL and BRD4 compared
to BRD2/3 may occur as a result of PROTAC binding,
triggering a more productive formation of a VHL:PRO-
TAC:BRD4 ternary complex. Elucidation of the molecular
basis for the BRD4-selective activity of PROTACs will warrant
further mechanistic investigation in the future. Our ﬁndings
demonstrating eﬀective and selective degradation of BRD4 with
a PROTAC approach open up unprecedented opportunities to
study the downstream physiological and pathological con-
sequences of BRD4 modulation. It will allow determination of
whether more selective pharmacological perturbations of BET
Figure 4. Selective degradation of BRD4 leads to a diﬀerential response between JQ1 and MZ1 on selected genes. mRNA expression proﬁles of
MYC, P21, AREG, FAS, FGFR1, and TYRO3 upon treatment with PROTAC MZ1 and JQ1 were compared. (a) HeLa cells were treated with 100 nM
MZ1, VHL-1′, or JQ1 or 0.01% DMSO vehicle control (Veh.) for 24 h. (b) To mimic the protein removal eﬀect, HeLa cells were transfected with
siRNA targeting individual BRD2, BRD3, or BRD4 or negative control siRNA and were harvested after 48 h. Quantitative PCR was performed to
analyze relative gene expression level of treated HeLa cells using target speciﬁc primers. Gene expression levels relative to GAPDH were normalized
to control treatment. The data shown represent the mean ± SEM (n = 3 technical replicates) of one experiment. Statistical signiﬁcance compared to
the control was determined with two-tailed t tests: *P < 0.05, **P < 0.01, ***P < 0.001, and n.s. = not signiﬁcant.
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protein function will have improved therapeutic eﬃcacy,
potentially leading to more eﬃcient and speciﬁc new drugs in
the future. Finally, potent chemical probes that bind to human
bromodomains outside the BET subfamily are beginning to
emerge,37 which could be similarly conjugated to a VHL ligand
to induce selective intracellular degradation of their respective
target bromodomain-containing proteins.
■ METHODS
For detailed descriptions of synthetic and biological methods, see the
Supporting Information.
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